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Summary The utility of serologic tests in the microbial diagnosis of orthopedic infections is
unknown. Antistreptolysin O titer determination is inexpensive and accurate in the diagnosis of b-
hemolytic group A, C, and G streptococci. In patients with negative culture results and positive
titers, antibiotics might be reduced to the narrowest spectrum, penicillin.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.Introduction
Orthopedic infections present a heavy burden for patients
and hospitals in terms of morbidity and associated costs. An
accurate microbiological diagnosis is the key factor for suc-
cessful antibiotic therapy, along with appropriate surgical
intervention and a multidisciplinary approach.
Stain or culture for identification of bacterial pathogens
must always be the first priority. Unfortunately the pathogens
cannot always be identified,1—3 frequently due to empirically
initiatedantibioticspriortohospitaladmission.Whentheinitial
oralantibiotic regimenfails,clinicians feelobligedtochange to
another empirical agent that usually has an even broader
spectrumthanthefirstagent.Thustheadvantagesofatargeted
antibiotictreatmentsuchaslowercosts,feweradverseeffects,* Corresponding author. Tel.: +41 22 372 9844; fax: +41 22 372 3987.
E-mail address: Ilker.Uckay@hcuge.ch (I. Uc¸kay).
1201-9712/$36.00 # 2008 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.10.004and less antibiotic resistance are lost. Polymerase chain reac-
tion (PCR) techniques formicrobiologicaldiagnosis areuseful in
partially treated infections, but are relatively expensive, not
always available, and require specimens from sterile body sites
to avoid contamination. PCR is rarely available inmany clinical
settings. Serologic tests in the timely diagnosis of acutemuscu-
loskeletal infections are useless.4
Although staphylococcal infections comprise up to two-
thirds of orthopedic infections,5,6 streptococci represent 7%5
or 9%6 of all causative pathogens in large series of orthopedic
infections. We investigated the value of obtaining serum
antistreptolysin O (ASO) titers in the diagnosis of orthopedic
infections due to streptococci.
Materials and methods
The University Hospital of Geneva is a 2200-bed tertiary
hospital with 41 000 annual admissions. The Orthopedic Sur-Published by Elsevier Ltd. All rights reserved.
Table 1 Key characteristics of the patients with specimens for serum antistreptolysin O.
Patient Sex Age,
years
Immunosuppression Infection Pathogens Bacteremia Delay,
infection—ASOa
ASO
titerb
1 M 44 - Hip prosthesis Staphylococcus
epidermidis
- 57 days <100
2 F 92 Diabetes Hip prosthesis Staphylococcus
epidermidis
- Unknown <100
3 M 82 Diabetes, hepatic
carcinoma
Diabetic foot
infection, abscess
Staphylococcus aureus - 40 days <100
4 F 73 - Knee arthritis Staphylococcus aureus - 12 days <100
15 days <100
5 F 40 - Knee arthritis Staphylococcus aureus - 105 days <100
6 F 42 - Tibial hardware Staphylococcus aureus - 32 days 200
78 days 200
7 M 64 Diabetes Hallux infection Staphylococcus aureus - 14 days <100
8 M 66 Diabetes Shoulder arthritis Staphylococcus aureus Yes 84 days 200
9 F 83 Diabetes, steroids
for pulmonary
fibrosis
Foot erysipela Staphylococcus aureus - 11 days <100
10 M 47 Diabetes Osteomyelitis femur,
leg abscess
Staphylococcus aureus - 5 days <100
12 days <100
11 M 77 Diabetes Diabetic foot
infection, abscess
Staphylococcus aureus - 12 days <100
Pseudomonas aeruginosa 19 days <100
Enterobacter cloacae
12 M 41 - Calcaneal hardware Enterobacter cloacae - 21 days <100
Pseudomonas aeruginosa
Enterococcus faecalis
13 F 73 Diabetes,
Horton’s
disease
Foot erysipela Escherichia coli - 16 days <100
Klebsiella oxytoca
14 M 37 - Arm phlegmon Peptostreptococcus spp - 9 days <100
15 M 67 Diabetes Leg erysipelas,
cutaneous abscess
Group C b-hemolytic
streptococci
- 3 days 100
16 F 80 - Knee prosthesis Group B b-hemolytic
streptococci
Yes 9 days 110
15 days <100
17 M 21 - Myositis leg Streptococcus pyogenes - 16 days 400
18 days 500
18 M 63 - Abscess leg Streptococcus pyogenes - 18 days 600
24 days 600
25 days 600
19 M 67 - Thumb phlegmon Streptococcus pyogenes - 6 days 300
8 days 600
9 days 600
20 M 17 - Foot abscess Group C b-hemolytic
streptococci
- 12 days 400
21 M 50 - Knee arthritis Group G b-hemolytic
streptococci
Yes 7 days 600
10 days 800
ASO, antistreptolysin O; M, male; F, female.
a Time delay between the clinical onset of infection and the day of the dosage of ASO.
b The cut-off for positive ASO titers is >200 U/ml.
422 I. Uc¸kay et al.gery Service has 119 acute care beds including a septic ward
with 22 beds, and performed 5374 surgical interventions in
2007. We searched the septic orthopedic database for
patients in whom the ASO titer was obtained along withspecies identification in the bacteriological laboratory. Inclu-
sion criteria were adult patients with orthopedic-related
infections and ASO titer samples during hospitalization for
that infection. To be included, patients had to have had a
ASO titers in orthopedic infections 423diagnosis of infection based on the presence of pus and the
growth of pathogens in microbiological cultures obtained
from intra-operative musculoskeletal biopsies or joint aspira-
tion. Exclusion criteria were culture-negative infections,
patients with infections other than orthopedic infections,
patients with post-streptococcal reactive arthritis,7,8 and
patients with rheumatic fever7,8 or sacroiliac joint disor-
ders.9,10
The culture of pathogens was performed according to
standard procedures.11 The ASO kit was a semi-quantitative
test with a cut-off value of 200 U/ml, and was based on
neutralization of rabbit blood hemolysis by the patient’s
serum antibodies. The streptolysin O for hemolysis was pur-
ified from Streptococcus pyogenes cultures. The cost of one
blood specimen for ASO titer (ASL-kit, bioMe´rieux Gene`ve)
was US$21.90.
Results
General
Data were retrospectively retrieved for 21 patients (seven
females, 14 males; median age 64 years) with 21 musculos-
keletal infections in whom ASO titer was performed in the
calendar year 2008 (Table 1). All patients had signs of infec-
tion according to the inclusion criteria. The mean maximum
C-reactive protein value was 117.4 mg/l (range 5—499 mg/l).
More than one specimen was obtained for ASO titer deter-
mination in nine patients. The first specimen was obtained at
a median of 13 days (range 3—105 days) after the clinical
onset of infection, and the last specimen at a median of 16
days. Test results were available within 1 and 5 days.
In those patients without ASO elevation, median titers
were 100 U/ml (range < 100—200 U/ml).
Elevated ASO titers
Five patients had elevated ASO titers (11 specimens; median
titer 600 U/ml, range 300—800 U/ml). These specimens were
takenbetweenday6andday25,withamedianvalueof14days
for the first specimen. One patient with elevated titers had
only one specimen sampled. Among the four other patients
with elevated ASO titers and multiple specimens, the titers
reached a plateau at day 8 and day 18 in two patients,
respectively, while they continued to rise at day 10 and day
18 in two other patients, respectively. All five patients with
elevatedASO titerswere treatedwith intravenous penicillin or
amoxicillin. All were curedwith no recurrence during a follow-
up period of at least three months.
The pathogens documented in the patients with elevated
ASO titers were S. pyogenes (b-hemolytic streptococci of
Lancefield group A; n = 3), b-hemolytic streptococci of group
G (n = 1), and b-hemolytic streptococci of group C (n = 1).
The pathogens of the patients without elevated ASO titers
are shown in Table 1.
Discussion
In thediagnosis ofmusculoskeletal infections byASO,we found
that the titers were consistently elevated only in infections
due to S. pyogenes (b-hemolytic streptococci of group A) andgroup G streptococci, and always negative for all other patho-
gens including Enterococcus, Peptostreptococcus, and b-
hemolytic streptococci of group B. A negative ASO titer was
also documented in one patient with group B arthritis.12 For
group C streptococci, ASO titers were positive in one patient
and negative in another patient. The negative result may have
been due to the fact that the specimen was obtained only 3
days after the onset of the infection and hence the time
interval was too short for the antibodies to have risen. We
foundonly one report describing highASO titers in five patients
with septic arthritis, however in the group with b-hemolytic
streptococci, the ASO level, and other details were not
reported.9 We did not have any false-positive results, i.e.,
elevated titers in non-streptococcal infections.
Streptolysin O is an exotoxin that repels leukocytes and
disrupts their membrane by pore forming or enzymatic attack
on phospholipids. It is produced by group A, C, and G strep-
tococci and Streptococcus canis.13,14 The streptolysin O of S.
pyogenes is within 90% genetic homology to the streptolysins
of S. canis and of group C streptococci.15 This explains why
the ASO titers in our series were only elevated among A, C,
and G streptococci and not in other streptococci or Enter-
ococcus.
In the infectious disease literature, ASO titers have been
used almost exclusively for epidemiological studies and the
clinical diagnosis of S. pyogenes infection16,17 and its seque-
lae, such as rheumatic fever, glomerulonephritis, and reac-
tive arthritis after throat infections.7—9 Gray et al. showed
that a single ASO titer greater than 400 U/ml correlated with
a sensitivity of 66% and specificity of 82% with upper respira-
tory tract infections due to S. pyogenes in adults.17 According
to the rheumatology literature, ASO titers may be elevated in
non-infectious arthritis9 and sacroiliac joint disorders in
genetically susceptible patients.10 b-Hemolytic streptococci
may trigger reactive arthritis as well as rheumatic fever.9
Consequently the distinction between reactive disease and
pyogenic infection has to be made clinically, which generally
is not difficult since orthopedic infections rarely affect
sacroiliac joints symmetrically in adults.12,18,19
Limitations of our study include its retrospective design
and small numbers of patients. Nevertheless, we think that
ASO titers are of value in cases of severe orthopedic infec-
tions whenever microbiological cultures remain negative.
ASO titer determination is relatively inexpensive and accu-
rate in the diagnosis of b-hemolytic groups A, C, and G
streptococci. These are the known pathogens in severe
infections such as necrotizing fasciitis20,21 and streptococcal
shock syndromes.20,22 Moreover, all three streptococci are
sensitive to penicillin G or amoxicillin.5,23 Therefore in
patients with a compatible clinical presentation, negative
culture results, and a positive result from titer evaluation,
antibiotics might be reduced to the narrowest but highly
active spectrum, i.e., penicillin. This attitude would support
the standard policy to narrow the antibiotic spectrum as
much as possible while preserving maximum activity, but it
has yet to be confirmed in large prospective trials.
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